Supply chains will need to continue to develop to adapt to a broad range of risks, from economic, social, and geopolitical.

Vibhu Tewary offers insight on this market segment, including a behind-the-scenes of what goes into designing a report. In this exclusive PC Podcast interview, Vibhu Tewary, project director, IQVIA ...

A session investigates the drivers of these shortages and ways to mitigate them. Another session along Trade & Channel Strategies’ supply chain, distribution, and logistics track focused on “Actions ...

As a result, the provider increases its involvement in the country’s pharma sector. LSPedia, a provider of software-as-a-service (SaaS) traceability solutions for the pharmaceutical industry, is ...

This website stores data such as cookies to enable essential site functionality, as well as marketing, personalization, and analytics. You may change your settings at any time or accept the default ...

PC: Back in August, you penned an article on "Enhancing Patient Access and Support Through Technology: A Comprehensive Assessment." What was the premise of the piece, and why exactly do you believe ...

A panel examines the gross-to-net bubble across various product mixes, how pricing impacts market access, and more. The third and final day of Trade & Channel Strategies in Philadelphia continued its ...

The 430,000 square-foot finished production facility will house multiple product types within the rare disease sector, including hemophilia. Novo Nordisk will be investing $1.2 billion toward the ...

Trade & Channel Strategies 2024: Key Challenges of Implementing Direct-to-Patient Models ...

Kevin O’Meara discusses Patient-Cetric 3.0 breakout session and the challenges of drug manufactures implementing Direct-to-Patient models.

The latest news for pharma industry insiders.